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RON2315: A novel human biologic for the topical treatment of psoriasis
T Gadek Rogne Bioscience, Portola Valley, CA
Psoriasis results from dysfunction in multiple components of the adaptive and inate immune systems. 
RON2315 is a novel, low MW (<1700 daltons), naturally occuring, human biologic capable of 
reducing inflammatory cytokine secretion from human and murine antigen presenting cells, macro-
phages and dendritic cells expressing the CMKLR1 G-protein coupled receptor. In particular, it tar-
gets the secretion of IL-12/23 and activation of the IL-17 axis in vitro, events which are mediated by 
myeloid dendritic cells. These cells are critical to the disease pathophysiology and have been shown 
to express CMKLR1 in the dermis of psoriatic plaques. Preclinical studies in vitro have demonstrated 
that secretion of a panel of cytokine message and/or protein levels under the control of NF-kB (IL-1b, 
IL-12/23(p40), TNF, IFNg, RANTES) are reduced by RON2315 at concentrations as low as 1 pM 
in response to a panel of inflammatory stimuli which all signal through NF-kB downstream of their 
individual receptors (LPS, Imiquimod, Zymosan, TNF, INFg, Chemerin). As a topical dermatologic 
agent, RON2315 has demonstrated >75% stability in culture with homogenized human skin for 
24 hours at 37 degrees, and topical formulations containing penetration enhancers have shown 
good transfer through the stratum corneum, epidermis and dermis of human skin ex vivo in Franz 
cell studies. In a vehicle controlled murine imiquimod model of IL-23 mediated skin inflammation, 
QD topical application of human RON2315 in a formulation effective in human skin penetration 
studies reduced inflammatory clinical scores of erythema in a dose dependent manner, exhibiting 
efficacy comparable to a single systemic dose of an anti-murine, anti-IL-23 mAb and better than 
topical Dexamethasone (1%). In an in vitro comparison of RON2315 (10 nM) to Dexamethasone 
(1 uM) in human dendritic cells stimulated with LPS, both molecules reduced total p65 levels in 
the NF-kB pathway by >75%. In summary, RON2315 is a highly potent, nonsteroidal modulator 
of IL-23 expression via the NF-kB pathway and offers promise as a novel human topical biological 
agent for the treatment of psoriasis and other hyperimmune diseases.    
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Blockade for CD155-TIGIT interaction is an effective therapy for melanoma
T Inozume,1 T Yaguchi,2 Y Kawakami2 and S Shimada1 1 Dermatology, University of 
Yamanashi, Chuo, Japan and 2 Division of Cellular Signaling, Keio University, Institute for 
Advanced Medical Research, Shinjyuku, Japan
Recent clinical trials show that the use of blockades for immune checkpoints via blocking anti-
bodies is a promising strategy for treating progressive tumors. Previously, we have shown that the 
CD155-TIGIT interaction is a novel immune checkpoint that negatively regulates anti-melanoma 
CTL response in vitro and in vivo. CD155 is highly expressed in melanoma cells, and is upregulated 
by IFNγ stimulation. The receptors CD226 (stimulatory) and TIGIT (inhibitory) control T-cell function 
through mechanisms analogous to those of the CD28/CTLA-4 interactions with CD80/CD86. In 
this study, we developed an experimental system using expanded tumor infiltrating lymphocytes 
(TILs) and an autologous melanoma cell line and confirmed the negative impact of CD155-TIGIT 
interaction on human TILs. Moreover, to develop a novel effective treatment for melanoma, we 
examined the effect of an anti-TIGIT blocking antibody. In the in vitro co-culture assay of mela-
noma cells and melanoma specific CTLs, the addition of the anti-TIGIT antibody enhanced IFNγ 
production of CD226+ CTLs via the phosphorylation of ZAP70. In the humanized mouse model 
using human melanoma cells and melanoma-specific human CTLs, the administration of anti-TIGIT 
antibody enhanced the anti-melanoma response of transferred CTLs. These results strongly suggest 
that the use of a blockade for TIGIT is an effective therapy for melanoma, similar to the blockade 
for CTLA-4 and PD-1.    
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Migratory DC temper subcutaneous immunity through key tolerance pathways
C Nirschl1, 2, Y Liu1, 2, S Mollah,3 RE Feder,3 P Wu1, 2, P Sage,2 AH Sharpe2 and 
N Anandasabapathy1, 2, 3 1 Department of Dermatology, Brigham and Women’s Hospital, 
Boston, MA, 2 Harvard Medical School, Boston, MA and 3 The Rockefeller University, New 
York, NY
Dendritic cells (DC) are critical for initiating immunity. The current paradigm in vaccine biology 
is that DC migrating from peripheral tissue and classical lymphoid resident DC cooperate in the 
draining lymph node to initiate priming and proliferation of T cells. We have previously established 
that subcutaneous immunity is Flt3L-dependent, controlled by cDC and actively tempered in vivo 
by migDC. Here, we demonstrate the suppressive roles of two unique genes, commonly shared by 
human and mouse migratory DC, in generating immunity following protein immunization. These 
data reveal protective immunity to protein vaccines is tempered by tolerogenic migratory DC, and 
identify key pathways involved in this tolerance program.    
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Rationale and design of a novel dendritic cell targeted vaccine for basal cell carcinoma
K Haitz1, 2, SR Barthel1, 2, Y Liu1, 2, C Nirschl1, 2, E Epstein3 and N Anandasabapathy1, 2 1 
Harvard Medical School, Boston, MA, 2 Department of Dermatology, Brigham and Women’s 
Hospital, Boston, MA and 3 Children’s Hospital Oakland Research Institute, Oakland, CA
Basal cell carcinoma (BCC) is commonly generated by Hedgehog signaling pathway mutations, most 
often in Patched 1. Hedgehog interacting protein 1 (HHIP1) is a hedgehog target overexpressed in 
BCC and other malignancies. Prior work has identified a portion of HHIP1 (pPT27) as immunogenic. 
Accordingly, we generated a novel dendritic cell (DC)-targeted vaccine aimed at BCC prevention 
by fusing pPT27 to an antibody recognizing DEC205, an antigen uptake receptor expressed on 
skin and lymph node resident DCs. Purified anti-DEC205-pPT27 bound with high specificity to 
CHO cells stably transfected with mouse DEC205, demonstrating proper synthesis and folding of 
the vaccine construct. Ongoing studies examine the immunogenicity of this vaccine and test its 
ability to generate protective immunity in a spontaneous BCC mouse model, Ptch +/- K14-Cre-ER 
p53 fl/fl, where we will analyze the effect on BCC tumor number, area, and burden. Innovative 
BCC vaccines could reduce high treatment costs and greatly improve quality of life for patients 
with basal cell nevus syndrome.    
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An ex vivo skin model that combines topical skin penetration and Th17 stimulation
M Bedard, S Cook, L Santos, J Neil, CE Peredo, SH Smith, J Cote-Sierra and J Lenn Stiefel, a 
GSK Co, Research Triangle Park, NC
For the first time we show a single integrated PK/PD model that can be used to establish the degree 
of target attainment from topical application for predictive modeling of clinical dosing. Previously, 
two separate models, one for pharmacokinetics (PK), the other for pharmacodynamics (PD), were 
required to predict clinical dosing such that a major limitation in developing topical novel chemical 
entities (NCEs) for dermatology has been that that there is no single model to establish PK/PD rela-
tionships. The in vitro skin penetration model using flow-through diffusion cells is a well established 
model for the study of percutaneous absorption and the determination of the PK of topically applied 
drugs. A newly developed PD model (J. Neil et al.), based in static Franz cells, looks at a molecule’s 
ability to penetrate the skin and engage its target to suppress the skin inflammatory response. Dose 
response data obtained from the two models independently can be combined for PK/PD modeling 
to help with predicting clinical dosing. However differences in experimental conditions between 
the two models vary significantly, including incubation, dosing, and study duration, which may 
impact the amount of drug delivered into the skin. Thus, it is unknown whether the degree of target 
engagement or inhibition of the inflammatory response observed in Franz cells corresponds to the 
tissue level concentrations measured using flow-through diffusion cells. This study sought to bridge 
the skin penetration (PK) and target engagement (PD) models by employing a tool compound over 
a dose range in Franz cells and measuring both drug concentrations in skin and mRNA levels of 
Th17 derived cytokines. Sample processing, separation of tissue layers, skin homogenization and 
compound extraction methodologies traditionally used in the PK model were adapted to the Franz 
cell to achieve this goal. Drug levels in the epidermis and dermis from the Franz cells were found 
to be at comparable amounts to those measured in the flow-through skin penetration assay across 
a range of 0.1% to 1% topical dose.    
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Immunomodulatory effects of AM1030, a topical 5-HT2B receptor antagonist in development 
for atopic dermatitis
N Palmqvist, M Siller, A Sjödin, H Arozenius, C Wenglén, A Ryde, L Pettersson, C Klint, 
A Pramhed, A Löfdahl and G Ekström AnaMar AB, Lund, Sweden
Serotonin (5-HT) is best known for its importance in the CNS. However, most 5-HT is found in the 
periphery. Being mainly synthesized in the gut, 5-HT is sequestered by platelets once it reaches the 
circulation. Upon localized activation of platelets in response to tissue injury or inflammation, the 
stored 5-HT is released to influence e.g. cytokine production, vascular permeability and pruritus. In 
this work we investigated the potential immunomodulatory effect of the 5-HT2B receptor antagonist 
AM1030, a compound currently evaluated in patients with atopic dermatitis. S. aureus enterotoxin 
A (SEA), a T-cell superantigen, was used to investigate the effect of AM1030 on T-cell-dependent 
responses in mice. AM1030 was administered s.c. 30 min before i.p. injection of a sublethal dose of 
SEA. The mice were euthanized 2 h after SEA injection and plasma was collected for ELISA analysis 
of IL-2, IL-12 and IL-17. To further study the effect of AM1030 on T-cell-dependent responses, the 
oxazolone-induced delayed-type hypersensitivity reaction was used. 7 days after sensitization, mice 
were challenged with a second application of oxazolone onto the right ear. AM1030 was applied 
topically onto the ear 15 min before and 15 min after challenge, and ear swelling was evaluated 24 
h later. Human peripheral blood mononuclear cells (hPBMCs) isolated from healthy donor blood 
were used to study the influence of AM1030 on SEA-induced cytokine production in vitro. Cell 
culture supernatants were collected after 48 h of incubation and cell viability was assessed. Super-
natant levels of IL-2, IL-5, IL-12 and IFN-γ were measured with ELISA. AM1030 dose-dependently 
decreased SEA-induced IL-2, IL-12 and IL-17 in mice. In the DTH model topical treatment with 
AM1030 significantly decreased ear swelling. In hPBMCs, AM1030 dose-dependently reduced the 
SEA-induced production of IL-2, IL-5, IL-12 and IFN-γ. To conclude, our results indicate immu-
nomodulatory effects of the 5-HT2B receptor antagonist AM1030 and support its potential as a 
topical treatment of AD.    
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Phenotypic analysis of dendritic cells infiltrating a spontaneous model of basal cell carcinoma
C Nirschl1, 2, Y Liu1, 2, P Wu1, 2, K Haitz1, 2 and N Anandasabapathy1, 2 1 Department of 
Dermatology, Brigham and Women’s Hospital, Boston, MA and 2 Harvard Medical School, 
Boston, MA
One in every three diagnosed cancers originates from the skin. Of these cases, 80% are basal cell 
carcinomas (BCC). Using a murine model of spontaneous BCC development (Ptch -/+ K14-Cre-ER 
p53 fl/fl), we investigated the impact of BCC tumor growth on a variety of resident as well as skin 
migratory DC populations. Interestingly, while tumor bearing animals had an overall decrease in the 
percentage of splenic MHCII+ Cd11chi resident DCs, this decrease was marked by an increase in the 
ratio of CD11b+ DCs to CD8a+ DCs. In contrast, in tumor draining lymph nodes no difference in 
the percent of either resident or migratory DC populations, was observed. Rather, the composition 
of the migratory DC population originating from skin (MHCIIhi Cd11cint) shifted in response to BCC 
tumors, increasing the percentage of Langerinpos DCs while decreasing the percentage of Langerinneg 
CD11b+ DCs. This increase in the Langerin+ DCs seemed to be driven by an influx of CD103+ 
migratory DCs. Surprisingly, within the tumor, approximately 30% of the CD45+ cells expressed 
high levels of both CD11c and MHC II, suggesting a DC origin. This population included Langerin+ 
CD103+ cells as well as CD11b+Langerinlow DCs and CD11b+Langerinint inflammatory monocytes, 
suggesting that both dermal migratory DCs as well as recruited monocytes are present within BCC 
tumors. These studies demonstrate that spontaneously developing BCC tumors have a significant 
effect on the composition of the migratory DC populations found in the tumor draining lymph node. 
Further studies will investigate the effects of BCC tumors on DC programming, both on intratumoral 
and migratory DCs and reciprocally will investigate the role of local DC on skin cancer growth.   
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Potential mechanisms for loss of hair follicle immune privilege in patients with alopecia areata 
following hepatitis B vaccination
C Richardson, E Gilmore and B Poligone Dermatology, University of Rochester Medical 
Center, Rochester, NY
Loss of anagen hair follicle immune privilege (HFIP) and changes in the ratio of activating to 
inhibitory NK cells are important in the pathogenesis of alopecia areata (AA). AA has been reported 
secondary to vaccination, most commonly following administration of the recombinant hepatitis B 
vaccine. How vaccination might lead to loss of HFIP is unknown. We report two pediatric cases in 
which AA was noted after receiving the recombinant hepatitis B vaccine. Both patients developed 
alopecia within two weeks of receiving the third dose. Potential mechanisms of loss of HFIP follow-
ing vaccination include increased interferon levels or an antigen-specific T-cell response. An EMR 
database search revealed an increased frequency of AA among those who receive the HBV vaccine 
(OR 2.7, p<0.0001). An independent analysis revealed an increased frequency of AA in those 
receiving interferon-beta treatment (OR 8.1, p<0.05). In order to explore whether an antigen-specific 
T-cell response might be elicited by HBV vaccination, a BLAST search was performed of all potential 
vaccine peptide fragments (6-mers) to look for identical human sequences. 120 human peptides 
were found to have exact sequence homology with part of the vaccine. While none of the 120 
peptides appeared to be specific to the hair follicle, two of the three longest peptides (8-mers) were 
from NK cell inhibitory receptors KIR3DL2 and KIR3DL1. Software (RANKPEP) designed to predict 
MHC:peptide binding demonstrated that, of the 218 potential 9-mers from the vaccine peptide, this 
KIR peptide is the most likely to bind HLA-DQ1, third most likely to bind HLA-DRB1*1104 (DR11), 
fourth most likely to bind HLA-Cw7*02, and one of only 18 predicted binders for HLA-DRB1*0401, 
all relevant MHC in AA. This suggests that hepatitis B vaccination has the potential to stimulate an 
immune response against KIR receptors. We present these data as two potential mechanisms for 
loss of HFIP following administration of the HBV vaccine.    
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CCL17 attenuates tumor immunity by increasing regulatory T cells and Th2 cells while 
decreasing myeloid-derived suppressor cells in tumor microenvironment
S Morimura,1 M Sugaya,1 T Oka,1 H Suga,1 T Miyagaki,1 Y Tsunemi,2 Y Asano,1 Y Tada,1 
T Kadono1 and S Sato1 1 Dermatology, University of Tokyo, Tokyo, Japan and 2 Dermatology, 
Tokyo Women’s Medical University, Tokyo, Japan
CCL17 is implicated in the pathogenesis of Th2 diseases such as atopic dermatitis. CCR4, a receptor 
for CCL17, is expressed on regulatory T cells (Tregs) as well as Th2 cells. In this study, we aimed to 
elucidate the role of CCL17 in tumor immunity using transgenic (Tg) mice overexpressing CCL17 in 
keratinocytes. Tumor formation was accelerated in CCL17-Tg mice when B16 melanoma cells were 
injected subcutaneously or intravenously. IL-10 and Foxp3 mRNA levels were significantly higher 
in the skin tumor and the draining lymph nodes of CCL17-Tg mice on day 14 after cutaneous inoc-
ulation than those of wild-type (WT) mice. Flow cytometric analysis also showed increase in CD4+ 
Foxp3+ cells in the lymph nodes of CCL17-Tg mice, suggesting that Tregs attenuated tumor immu-
nity. Elevated IL-4 mRNA levels and increase in CCR4+ cells in the skin and lung tumor of CCL17-Tg 
mice suggested that more Th2 cells infiltrated into the tumor microenvironment, which may also be 
involved in impaired tumor immunity. Interestingly, the frequency of myeloid-derived suppressor 
cells (Gr-1+ CD11b+ cells), which accelerate tumor progression, was significantly decreased in the 
skin and lung tumor of CCL17-Tg mice and it negatively correlated with the frequency of CCR4+ 
cells. Peritoneal injection of anti-CD25 antibody (Ab) one day before tumor inoculation slightly 
decreased tumor volume in WT mice, suggesting that depletion of Tregs enhanced tumor immunity. 
Treatment with anti-CD25 Ab remarkably reduced tumor volumes in CCL17-Tg mice, which was 
much smaller than those in WT mice injected with the same Ab. Thus, CCL17 attenuates tumor 
immunity by increasing Tregs and Th2 cells while it decreased myeloid-derived suppressor cells, 
which may work as a “safety-net” to reduce the risk of malignancy in Th2-dominant environment.   
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Distinctive downmodulation of plasmacytoid dendritic cell by vitamin D3 analogue in its 
interferon-α production and chemotactic activity
T Suzuki and Y Tokura Hamamatsu University School of Medicine, Hamamatsu, Japan
Vitamin D3 analogues are widely used in the treatment of psoriasis, however, their direct actions 
on the cytokine production and chemotaxis activity of plasmacytoid dendritic cells (pDCs) remain 
unelucidated. We investigated the effects of vitamin D3 analogue calcipotriol (CAL) in parallel with 
other psoriasis drugs on pDCs and conventional DCs (cDCs), focusing on the cytokine secretion 
and chemotaxis. For cytokine production, we compared in mice the effects of CAL, cyclosporine 
A (CyA), and triamcinolone acetonide (TA) on the IFN-α production by pDCs, TNF-α produc-
tion by cDCs, and IFN-γ production by T cells. pDCs were isolated from mouse spleen cells and 
stimulated with CpG-ODN. Crude spleen cells were stimulated with CpG-ODN for cDCs or with 
concanavalin A for T cells. Each drug was added at the beginning of culture. The cytokines in the 
48-hr culture supernatants were quantified by ELISA. For chemotaxis, we evaluated the ability of 
CAL to inhibit the chemotaxis of freshly isolated pDCs toward chemerin by a real-time monitoring 
method, EZ-Taxiscan. In addition, we assessed the effect of CAL on pDC accumulation in vivo 
by painting CAL ointment to the mouse skin inflamed by imiquimod cream. 440c+ pDCs were 
enumerated by immunohistochemistry, and pDC-associated cytokines were evaluated by real-
time PCR. CAL significantly inhibited IFN-α production, whereas it did not substantially reduce 
TNF-α or IFN-γ. On the contrary, CyA did not inhibit IFN-α production, but did suppress TNF-α 
and IFN-γ production. TA inhibited the cytokine production by all cell types. CAL suppressed the 
CpG-augmented expression of MyD88 and TLR9. In the chemotaxis assay, highly purified pDCs 
migrated toward chemerin, which was significantly downmodulated by CAL. CAL depressed the 
expression of chemerin receptor CMKLR1 on pDCs. In addition, the recruitment of pDCs to the 
imiquimod-applied skin was reduced by simultaneous application of CAL along with reduction of 
mRNA expression of IFN-α2. Thus, CAL uniquely downmodulates the cytokine production and 
chemotactic activity of pDCs.    
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A wave of regulatory T cells into neonatal skin mediates tolerance to commensal microbes 
TC Scharschmidt,1 KS Vasquez,1 H Truong,1 SV Gearty,1 ML Pauli,1 A Nosbaum,1 M Otto,4 
JJ Moon,5 AK Abbas,2 MA Fischbach3 and MD Rosenblum1 1 Dermatology, UCSF, San 
Francisco, CA, 2 Pathology, UCSF, San Francisco, CA, 3 Bioengineering, UCSF, San 
Francisco, CA, 4 National Institute of Allergy and Infectious Disease, Bethesda, MD and 5 
Center for Immunology & Inflammatory Diseases, MGH, Charlestown, MA
Each centimeter of our skin contains over a million lymphocytes and a million commensal bac-
teria. Very little is known about how the cutaneous immune system continuously senses antigens 
from commensal bacteria without causing destructive inflammation. To elucidate how adaptive 
immune tolerance is established and maintained to skin commensal microbes, we engineered a 
prototypical skin commensal (S. epidermidis) to express the model antigen 2W (Epi-2W), allowing 
us to comprehensively analyze commensal-specific CD4+ T cell responses in the context of both a 
polyclonal T cell repertoire and a complex microbiome. Using this system, we observed that skin 
colonization during a defined period of neonatal life was required to establish tolerance to Epi-2W. 
In contrast, colonization of adult skin with Epi-2W failed to establish tolerance. On examination, we 
found that the first weeks of life are characterized by an abrupt wave of highly activated regulatory 
T cells (Tregs) that accumulate in skin. Inhibition of Treg migration into skin during this period 
completely abrogated tolerance to Epi-2W. Ongoing work suggests that a hair-follicle derived 
chemokine may direct migration of Tregs into skin during this window. Our results demonstrate 
that the host-commensal relationship in skin relies on a unique population of Tregs that control 
antigen-specific responses directed at skin microbes, and that there is a critical developmental 
window in which this tolerance is established. This suggests that composition of the cutaneous 
microbiome in the neonatal period has formative effects that shape the adaptive immune response 
to bacterial antigens and that disrupting the cutaneous host-commensal relationship early in life 
may have enduring health implications.    
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Keratin 17 enhances the chemotaxis of neutrophils through regulating chemokine CXCL1 
secretion in keratinocytes via PI3k/AKT/NF-κB pathway
L Jin, E Dang, C Han, B Li, M Jiang and G Wang Department of Dermatology, Xijing Hospital, 
Fourth Military Medical University, Xi’an, China
Keratinocytes not only form and renew the skin barrier but also play a key role in the skin’s immune 
response. Under the pathological condition the immune function of keratinocytes is activated 
following the expression of keratins variation. Keratin 17 (K17) belongs to the human type I epi-
thelial keratins and provides mechanical support within cells. There is growing evidence that it is 
associated with proliferation, apoptosis, development, and tumorigenesis. We previously reported 
aberrant expression of K17 in the suprabasal keratinocytes and its immune-associated function in 
psoriasis. However, the relationship between K17 and immune function of keratinocytes remain 
poorly defined.Microarray analysis of keratinocytes revealed the relationship between K17 and 
CXCL1. We used real-time PCR, western blotting, immunohistochemistry, immunofluorescence, 
and ELISA to determine that K17 upregulated CXCL1 expression in 20 clinical samples, primary 
keratinocytes, and in the SCID-hu xenogeneic transplantation and imiquimod-induced psoriatic 
mouse models. The PI3k/AKT/NF-kB pathway in keratinocytes was involved via specific inhibitors 
and siRNA. In addition, K17 induced keratinocyte-mediated chemotaxis of neutrophils by upreg-
ulating the expression of CXCL1 in the Transwell cell model and in imiquimod-induced psoriatic 
mice. All experiments were repeated 3 times; however, we did not perform the experiment in CXCL1 
knockout transgenic mice. The function of the regulation in vivo needs to be elucidated further.
In conclusion, K17 promotes the CXCL1-mediated chemotaxis of neutrophils through PI3k/AKT/
NF-kB pathway in psoriatic keratinocytes. We demonstrated that K17, a type I keratin, modulates 
keratinocyte immune function. Our findings show that K17 is a marker of proliferation and func-
tions in immune modulation in keratinocytes. Our results remind us that we should re-evaluate the 
function of keratin in keratinocytes, as it may be a key contributor to inflammatory skin diseases.   
Adaptive Immunity & Vaccination | ABSTRACTS
www.jidonline.org   S3
013
Contributions of skin resident and recirculating memory T cells to depigmentation in vitiligo
J Richmond, M Rashighi, P Agarwal and JE Harris Medicine, Division of Dermatology, 
University of Massachusetts Medical School, Worcester, MA
Vitiligo is a disfiguring, depigmenting autoimmune skin disease that is mediated by CD8+ T lym-
phocyte killing of melanocytes. Depigmentation often recurs at the same location after therapy is 
discontinued, and the mechanism for this is unknown. Viral infections of the skin generate both 
central memory T cells (Tcm) that localize to lymph nodes and recirculate, as well as resident 
memory T cells (Trm) that remain in the skin for very long periods, and both populations help 
prevent reinfection. We hypothesized that melanocyte-specific Trm persist within vitiligo lesions 
and make them refractory to treatment. To test this hypothesis, we examined phenotypes of auto-
reactive T cells in a mouse model of vitiligo and found distinct populations of melanocyte-specific 
Tcm (CD44+CD62L+) in lymph nodes and Trm (CD44+CD69+CD103+) in depigmented skin. To 
determine whether Trm are sufficient for inducing vitiligo, we transplanted depigmented tail skin, 
which contains Trm, from vitiligo mice onto the back of naïve recipients. This resulted in rapid 
repigmentation of grafted skin, suggesting that Trm are not sufficient for disease. To determine 
whether Tcm are sufficient for inducing vitiligo, we adoptively transferred Tcms from vitiligo mice 
into naïve recipients and found they were not sufficient for inducing disease. However, transferring 
both skin and Tcms induced de novo depigmentation. To confirm the need to recruit Tcms to main-
tain lesions, we treated depigmented mice with the S1P1 inhibitor FTY720, which prevents Tcm 
from exiting the lymph node and re-entering the skin. This resulted in rapid repigmentation despite 
no effect on Trm numbers in the epidermis, indicating that Tcms participate in the maintenance of 
depigmentation. However, targeting Tcm would not likely provide a durable response due to the 
resilience of Trm, which can persist in the skin. Based on these data and clinical observations, we 
propose that depleting Trm may prove to be a highly effective and more durable treatment than 
existing strategies for vitiligo.    
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Acne vaccines targeting secretory CAMP factor of Propionibacterium acnes
C Huang Division of Dermatology, University of California, San Diego, San Diego, CA
Acne vulgaris afflicts more than forty million people in the United State alone, and despite the 
multitude of the products on the market, there is still no effective treatment that can prevent and 
cure this disease. The severity of acne vulgaris is highly associated with the inflammatory response 
to Propionibacterium acnes (P. acnes), an opportunistic skin bacterium. The goal of our project is 
to educate the immune system of acne patients in order to allow their body to naturally control the 
growth of P. acnes. This approach has the potential to result in a long term cure of the disease. Our 
approach is based on our discovery of a weak link in P. acnes that drives the disease. This molecule is 
known as the secretory Christie-Atkins-Munch-Peterson (CAMP) factor. Because of antigen masking, 
the body can not normally neutralize CAMP factor. Our laboratory has discovered a method to 
overcome this and has publications and preliminary data that show this can prevent inflammation 
caused by P. acnes in mice and in human acne tissues. Vaccination using surface sialidase or heat 
killed P. acnes as an antigen significantly suppressed P. acnes-induced inflammation. Monoclonal 
antibodies to CAMP factor and sialidase exhibit the neutralizing capability to attenuate the produc-
tion of IL8 in ex vivo explants obtained from acne patients. We are seeking collaboration to further 
validate this method and confirm the significance of CAMP factor as a driver of inflammation in 
humans. We believe that if this proposal is successful, this approach could be translated into use 
for humans in the very near future.    
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Identifying Merkel polyomavirus-specific CD4+ and CD8+ T-cells in Merkel cell carcinoma 
patients’ tumor-infiltrating lymphocytes
D Ibrani,1 JG Iyer,1 N Vandeven,1 N Miller,1 O Afanasiev,1 D Koelle1, 2 and P Nghiem1, 2 1 
Medicine, University of Washington, Seattle, WA and 2 Fred Hutchinson Cancer Research 
Center, Seattle, WA
Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer in which 80% of cases are driven 
by the Merkel cell polyomavirus (MCPyV). Persistent expression of small and large T antigens (T-ag) 
is required for tumor growth. Identification of CD4+ and CD8+ T-cell epitopes within MCPyV 
T-ag is required to create tumor virus-specific tetramers to track T-cell frequency, phenotype and 
function, as well as to measure change in patients’ immune responses with immunotherapy. Clin-
ical grade tetramers can also be used for adoptive T-cell therapy. We cultured tumor-infiltrating 
lymphocytes (TIL) from 60 MCC tumors from 42 patients to identify MCPyV-specific T-cell epitopes 
using interferon-gamma intracellular cytokine cytometry. Among the 42 patients’ TIL that were 
screened, 19 (45%) responded to at least one MCPyV peptide pool. In total, we have now identified 
8 MCPyV-specific T-cell epitopes using cultured TIL; most recently, we identified 4 novel CD8+ 
T-cell epitopes and 1 novel CD4+ T-cell epitope. Of the 4 unique CD8+ T-cell responses, HLA 
restriction was determined for 3, one of which has yielded a tetramer useful for an ongoing adop-
tive T-cell therapy clinical trial. MCPyV-specific CD4+ and CD8+ T-cells are present in ~50% of 
expanded TIL from MCC tumors. Identification of these MCPyV T-cell epitopes will enable tracking 
of MCPyV-specific T-cells in blood and detailed biomarker studies of responses to immune therapies 
including PD1-axis blockade.    
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Regulatory T cells facilitate cutaneous wound healing
A Nosbaum,1 M Ettinger,1 H Truong,1 ML Pauli,1 SV Gearty,1 AK Abbas2 and MD Rosenblum1 
1 Dermatology, University of California - San Francisco, San Francisco, CA and 2 Pathology, 
University of California - San Francisco, San Francisco, CA
Skin wound healing is a complex process involving precise coordination between immune cells and 
tissue parenchymal cells. The potential role of regulatory T cells (Tregs) in repairing wounded skin 
is currently unknown. We hypothesize that Tregs play a major role in facilitating wound healing 
by regulating the function of macrophages and tissue fibroblasts. To test this hypothesis, we char-
acterized Tregs in wounded skin. We established a mouse wound healing model and showed that 
Tregs accumulate, are highly activated, and markedly proliferate in skin early after wounding. Treg 
depletion attenuated normal wound closure and was associated with increased pro-inflammatory 
macrophages. Only Treg depletion during the first 5 days post-wounding resulted in delayed wound 
closure. To test whether Tregs directly influence fibroblast function, we examined the interaction 
between human Tregs and dermal fibroblasts using an ex vivo coculture system. In these assays, 
Tregs inhibited the fibroblast to myofibroblast transition, as evidenced by reduced fibroblast expres-
sion of alpha-smooth muscle actin (a-SMA). Taken together, these results suggest that Tregs play 
a major role in cutaneous wound healing by directly influencing fibroblast function. These results 
have implications in our understanding of how tissue fibrosis is regulated in wound healing and 
chronic fibrosing disorders of the skin.    
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Quantification of CD69+CD103+ skin TRM cells in chronic atopic dermatitis
S KIM1, 2, C Park,3 J Shin,1 J Noh,1 S Jin1, 2, H Lee,1 J Lee,1 TS Kupper3 and KH Lee1, 2 1 
Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University 
College of Medicine, Seoul, Korea (the Republic of), 2 Brain Korea 21 PLUS Project for 
Medical Science, Yonsei University College of Medicine, Seoul, Korea (the Republic of) and 
3 Dermatology, Brigham and Women’s Hospital, Boston, MA
Atopic dermatitis(AD) is a highly pruritic, chronic relapsing inflammatory skin disease character-
ized by significant T-cell infiltration, and frequently recurs in the same areas of the skin and even 
resolved skin keeps the disease memory. While the role of TRM cells has been well studied in the 
chronic inflammatory skin diseases such as psoriasis that have a relapse in the same sites, TRM 
cells in AD has not yet been known. In this study, thus, we evaluated the ratio of dermal CD4 and 
CD8 T cells, and expression of TRM cell markers(CD69 and CD103) using immunofluorescence 
staining in chronic AD and normal human skin tissues. The percentage of CD3+CD4 T cells among 
the entire mononucleated cells (DAPI+ cells) in the dermis was 25-30% in chronic AD skin, and 
15-20% in normal skin. While the percentage of CD3+CD8 T cells was less than 10% in normal 
skin, chronic AD skin had around 20% of CD3+CD8 T cells among total dermal DAPI+ cells. We 
also observed that the percentages of CD4+CD69+, CD4+CD69- T cells within dermal CD3+CD4 T 
cells were 94.74%, 5.26% in chronic AD skin and 62.07%, 37.93% in normal skin, and those of 
CD4+CD103+, CD4+CD103- T cells were also 97.22%, 2.78% in chronic AD and 44.44%, 55.56% 
in normal skin, respectively. While dermal CD8+CD69+, CD8+CD69- T cells constitute 90.38%, 
9.62% of chronic AD skin and 55.56%, 44.44% of normal skin, CD8+CD103+, CD8+CD103- T cells 
comprised 75.76%, 24.24% in chronic AD and 67.74%, 32.26% in normal skin. We also found that 
CD69+CD103+ CD4 and CD8 TRM cells in chronic AD skin resided in upper dermis prominently 
compared to normal human skin. These results suggest that significant population of CD69+CD103+ 
skin TRM cells may play a role in pathogenesis of chronic AD that recurs in the same area.    
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Shared VH1-46 antibody gene usage in pemphigus vulgaris predicts antibody cross-reactivity 
to desmoglein 3 and rotavirus VP6
MT Cho,1 C Ellebrecht,1 CM Hammers,1 G Sapparapu,2 J Crowe2 and AS Payne1 1 
Dermatology, University of Pennsylvania, Philadelphia, PA and 2 Vanderbilt Vaccine Center, 
Nashville, TN
Pemphigus vulgaris (PV) is a potentially fatal skin blistering disease caused by autoantibodies 
(autoAbs) to desmoglein 3 (Dsg3). Previously, we identified shared VH1-46 Ab variable gene usage 
in the anti-Dsg3 repertoire among 4 PV patients by high throughput B cell receptor (BCR) cloning. 
Somatic mutation reversion studies indicated VH1-46 BCRs required few to no acidic amino acid 
mutations to acquire Dsg3 reactivity, which may favor their early selection in the immune response. 
Interestingly, shared VH1-46 gene usage also occurs in the B cell response to rotavirus protein VP6, 
and similarly, few somatic mutations are required for VH1-46 BCRs to bind VP6. We thus inves-
tigated whether Dsg3-reactive VH1-46 BCRs are cross-reactive to VP6 and/or clonally related to 
VP6-reactive BCRs within the same patient, which may explain the tolerance of these autoreactive 
clones. We screened a combinatorial library of ~108 PV IgM B cell clones against Dsg3 and VP6 
which identified 13 unique H-CDR3 clonotypic families. 7/13 families used VH1-46, reflecting 
enrichment of VH1-46 clones by Dsg3/VP6 antigenic selection. ELISA and immunofluorescence 
(IF) studies confirmed that of the 6 VH1-46 clonotypes able to be expressed and purified as soluble 
Abs, 5 cross-reacted to VP6 and Dsg3, while 1 bound VP6 but only weakly bound Dsg3 without 
appreciable IF binding to human skin. Additionally, 3 of 5 VH1-46 anti-Dsg3 IgG clonotypes 
previously isolated from 3 different PV patients cross-reacted to VP6 in either their somatically 
mutated or unmutated form. Our data suggest that a VH1-46 B cell response to rotavirus may be 
an initiating event that develops into an autoimmune response to Dsg3 in susceptible individuals.   
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Next generation T cell receptor sequencing reveals complex T cell dynamics in Alopecia 
Areata 
A de Jong,1 L Xing,2 A Jabbari,1 Z Dai,1 VH Price,3 M Duvic,4 D Norris,5 M Hordinsky,6 
J Mackay-Wiggan,1 R Clynes1 and A Christiano1, 7 1 Dermatology, Columbia University, 
New York, NY, 2 Pathology, Columbia University, New York, NY, 3 Dermatology, UCSF, 
San Francisco, CA, 4 Dermatology, Anderson Cancer Center, Houston, TX, 5 Dermatology, 
Univ of Colorado, Denver, CO, 6 Dermatology, Univ of Minnesota, Minneapolis, MN and 7 
Genetics and Development, Columbia University, New York, NY
Alopecia Areata (AA) is a T cell mediated autoimmune disease, characterized by non-scarring 
hair loss. Using T cell receptors (TCR) as unique identifiers for T cell clones, high throughput TCR 
sequencing has enabled us to perform detailed quantitative analysis of the T cell repertoire during 
the course of AA. In the C3H/HeJ mouse model of AA, in which hair loss is induced using grafting 
of alopecic skin, we analyzed the TCR repertoire of donor skin, and followed the TCR repertoire 
in recipient skin before grafting, and 3 and 6 weeks after grafting. This analysis showed that an 
influx of expanded T cell clones coincides with the onset of hair loss, and that the T cell repertoire 
in affected skin shows significantly higher clonality than unaffected skin. The T cell clones present 
in affected skin are detected in the CD8+CD44highCD103highNKG2D+ fraction of the skin draining 
lymph nodes. The limited overlap between TCR nucleotide sequences in affected skin of donors 
and recipients, suggests that this skin graft model does not simply represent transfer of pathogenic 
T cell clones present in the graft, but instead, that novel pathogenic T cells are primed in the recip-
ients. Notably, however, at the protein level there was significant overlap in TCR CDR3 sequences 
between individual mice, which strongly supports the notion that AA is an antigen driven disease. 
In human AA, TCR repertoire analysis showed that T cell clones unique to lesional skin are gener-
ally not detected in blood, suggesting that local T cell expansion occurs at the site of disease. This 
comprehensive analysis of the TCR repertoire using high throughput TCR sequencing provides novel 
insights in the pathogenesis of this autoimmune skin disease.    
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Calcitonin gene-related peptide (CGRP) induces endothelial cells (EC) to bias Langerhans cell 
(LC) antigen presentation towards a Th17 response through induction of soluble mediators
W Ding, LL Stohl, JA Wagner, L Xu and RD Granstein Weill Cornell Medical College, New 
York, NY
We have previously reported that exposure of murine primary dermal microvascular ECs to CGRP 
endows them with the capacity to bias the outcome of antigen presentation by LCs to responsive T 
cells toward the Th17 pole. We have now asked whether ECs must be in contact with LCs and/or T 
cells for this to occur. Twelve thousand five hundred primary dermal microvascular ECs (BALB/c) per 
well were plated in the lower compartment of 96-well Transwell plates and 24 hours later treated 
for 3 hours with 100 nM CGRP or medium alone. Cells were then washed extensively and 1.25 x 
104 LCs from BALB/c mice and 2.25 x 105 CD4+ T cells from DO11.10 transgenic mice (BALB/c 
background) were added to the upper compartment of each well in the presence or absence of 10 
μM cOVA323-339. Supernatants were harvested 48 hours later and analyzed for cytokine content. 
Addition of CGRP-exposed ECs significantly enhanced IL-6 and IL-17A production compared to 
wells containing medium-treated ECs while significantly inhibiting interferon gamma (IFNγ) and IL-4 
production. Similar experiments were also set-up in standard wells in the same manner utilizing ECs 
pre-treated with small inhibitory RNA (siRNA) to IL-6 or scrambled siRNA. Pre-treatment with IL-6 
siRNA significantly inhibited the increased IL-17A and IL-6 production while significantly reducing 
the inhibition of IFNγ production. Only a slight, but significant, reversal of the effect of CGRP expo-
sure by siRNA treatment was seen on the inhibition of IL-22 production and no effect was seen on 
suppression of IL-4. These data demonstrate that the ability of CGRP to bias the outcome of antigen 
presentation through actions on ECs depends, at least in part, on release of soluble mediators. Many, 
although not all, of these effects can be attributed to production of IL-6 by CGRP-treated ECs. These 
results suggest a locus for possible therapeutic manipulation in diseases characterized by unwanted 
or inappropriate Th17 cell activity.    
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Elevated thymic stromal lymphopoietin expression in the skin blocks breast carcinogenesis
S Demehri,1 TJ Cunningham,1 S Manivasagam,1 M Meyer,1 D Denardo,1 R Kopan2 and 
W Yokoyama1 1 Washington University School of Medicine, St. Louis, MO and 2 Cincinnati 
Children’s Hospital, Cincinnati, OH
Breast cancer is the second most common type of cancer among women in the United States 
affecting 12.4% of women with 40,000 deaths estimated each year. Epidemiological data suggest 
that individuals with the history of allergic diseases like atopic dermatitis and asthma have reduced 
risk of developing breast cancer. However, a mechanistic link between the atopic disease and breast 
cancer protection is lacking. Herein, we demonstrate that Thymic Stromal Lymphopoietin (TSLP) 
released from the skin blocks breast cancer development in mice. TSLP is an epithelial-derived 
cytokine that is a master regulator of allergic inflammation in the skin and lung. We have previously 
shown that epidermal-derived TSLP blocks skin cancer. We have also shown that TSLP released from 
keratinocytes can reach high levels in the systemic circulation and cause allergic inflammation at 
distant organs. Therefore, we hypothesized that skin-derived TSLP can impact breast carcinogenesis 
by inducing an anti-tumor immunity in the breast. We used a spontaneous model of breast cancer in 
mice (MMTV-PyMT+/tg) and crossed them to animals overexpressing TSLP in their skin (K14-TSLP+/
tg). Interestingly, we found that overexpression of TSLP in the skin and its high circulating levels led 
to significant resistance against breast cancer development (p<0.001). The tumors in K14-TSLP+/
tg,MMTV-PyMT+/tg mice were largely arrested in the early adenoma stages and these mice were 
protected from developing metastatic disease. We observed a massive accumulation of activated 
CD4+ T helper 2 (Th2) cells in the breast tumors and their draining lymph nodes in K14-TSLP+/
tg,MMTV-PyMT+/tg mice compared to the MMTV-PyMT+/tg animals. The Th2 cells were both required 
and sufficient to establish a robust tumor immunity against breast cancer. Therefore, our findings 
establish a novel mechanistic explanation for the reduced risk of breast cancer in atopic patients.   
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Topical application of eupatilin ameliorates atopic dermatitis-like skin lesions of NC/Nga mice
J Lee, Y Lee, J Lee and Y Park Seoul St. Mary’s Hospital, Seoul, Korea (the Republic of)
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder with intense pruritus. 
Eupatilin (5,7-dihydroxy-30,40,6-trimethoxyflavone), is the major lipophilic flavonoid from Arte-
misia umbelliformis Lam. and Artemisia genipi Weber. Although it has been reported to play a role 
in inflammatory responses, its action on AD is unclear. In this study, we assessed whether topical 
eupatilin application could suppress AD-like skin lesions of NC/Nga mice. Eupatilin was topically 
applied to ears induced by repeated application of 0.2-1% DNCB twice a week for 3 weeks in 
a murine AD model. The efficacy of topical eupatilin treatment was evaluated by assessing skin 
severity score, ear thickness and histology. In addition, mRNA expression of proinflammatory and 
inflammatory cytokines was measured by real-time RT-PCR. The eupatilin significantly reduced the 
skin severity score and ear thickness (P < 0.05). Topical application of eupatilin also reduced inflam-
matory cell infiltrations including mast cells in the dermis. Eupatilin also significantly decreased the 
mRNA and protein expression of IL-4, thymic stromal lymphopoietin, TNF-α, IL-17 and IL-19 (P < 
0.05). Based on these results we suggest that topical application of eupatilin could be a promising 
therapeutic modality for AD.    
023
CD8αα+ T cells contribute to lichen planus independence of LAMP1-meditated degranulation
X Sun, B Li and G Wang Department of Dermatology, Xijing Hospital, the Fourth Military 
Medical University, Xi’an, China
Background: Lichen planus is CD8+ T cells-mediated chronic inflammatory skin disease. CD8+ 
T cells, including CD8αα+ and CD8αβ+ T cells, exhibit distinct functions in immune response. 
CD8αβ+ T cells kill target cells by lysosomal-associated membrane protein 1 (LAMP-1)-mediated 
cytotoxin release. While CD8αα+ T cells are mainly link to mucosal immune response. The aim of 
our study was to investigate which subpopulation of CD8+ T cells contribute to lichen planus and 
the underlying mechanism. Methods: Lichen planus lesions, normal skins and blood samples were 
harvested from 20 patients and 20 healthy volunteers. Immunofluorescence assay was used to detect 
the coexpressions of CD8α, CD8β, LAMP-1, granzyme B and perforin in the lichen planus lesions 
and normal skins. Flow cytometry was performed to analyze the levels of granzyme B, perforin and 
LAMP-1 expressed in circulating CD8αα+ T cells and CD8αβ+ T cells in patients and healthy con-
trols. Results: By using immunofluorescence assay, we found that CD8αα+ T cells were abundantly 
distributed in the upper dermis of the lichen planus lesion, while a small number of CD8αβ+ T cells 
were only seen around blood vessels in the medial dermis. In addition, we showed that granzyme 
B and perforin were abundantly expressed in CD8αα+ T cells in the lesion. Nevertheless, we didn’t 
detect expression of LAMP-1 in CD8αα+ T cells. Further, by flow cytometry assay, we found that 
granzyme B and perforin were expressed comparably in CD8αα+ T or CD8αβ+ T cells between 
patients and healthy controls. Surprisingly, our results showed that in both patients and healthy 
controls, CD8αα+ T cells produced more granzyme B and perforin than CD8αβ+ T cells. However, 
these CD8αα+ T cells expressed lower LAMP-1 compared with CD8αβ+ T cells. Conclusion: Our 
results suggested that CD8αα+ T cells play a crucial role in the pathogenesis of lichen planus by 
releasing granzyme and perforin. However, different from CD8αβ+ T cells, CD8αα+ T cells releasing 
these cytotoxins are independent of LAMP-1.    
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Immunomodulatory effects of nanoparticles on the contact hypersensitivity response in 
C57BL/6 hairless mice
S Jatana,1 BC Palmer2 and LA DeLouise3, 1, 2 1 Biomedical Engineering, University of 
Rochester, Rochester, NY, 2 Toxicology, University of Rochester, Rochester, NY and 3 
Dermatology, University of Rochester, Rochester, NY
Skin is the main route to allergen sensitization and provides innate as well as adaptive immune func-
tions to maintain homeostasis. Skin antigen presenting cells (APCs) generate an immune response 
following allergen exposure as in the case of Allergic Contact Dermatitis (ACD). Common ACD 
allergens include urushiol in poison ivy and nickel in jewelry. APCs sensitize effector CD4+ and 
CD8+ T cells in the lymph nodes against topical allergens at the point of first contact and a subse-
quent exposure can cause pruritic rash and/or swelling generated by the antigen-specific T cells. 
An in vivo mouse model of Contact Hypersensitivity (CHS) is commonly used to study the allergic 
response to chemical haptens like dinitrofluorobenzene (DNFB), a Th1 hapten. In this study we 
investigate a novel CHS model to explore the immunomodulatory effects of nanoparticles (NPs) on 
the allergic response induced in the skin by DNFB. Glutathione coated quantum dots (GSH QDs, 
-ve charge) were incorporated in both the sensitization and challenge phase along with DNFB and 
the ear swelling response was measured. The 0.2% DNFB treated ear exhibited the expected ear 
swelling response, however, when the ear was co-challenged with GSH QDs and DNFB the swelling 
response was inhibited (p<0.05). Fewer DNFB-protein adducts and cell infiltrates were observed in 
the GSH QD co-challenged ear (compared to control). This suggests that the GSH QDs modulate 
the immune response specifically in the challenge phase. Gold and silica NPs also significantly 
reduced the ear swelling response in the challenge phase (compared to control, p<0.05), whereas, 
titanium dioxide and carbon nanotubes did not. These findings suggest an opportunity to develop an 
NP based therapeutic for treating/preventing skin inflammation. On-going studies seek to examine 
the extensibility of our findings to other Th1 and Th2 sensitizing agents and to develop a cellular 
and molecular level understanding of the immunosuppressive mechanism.    
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Capturing functional conservation between human skin and mouse DC systems for generating 
better vaccines
E Klechevsky Pathology and Immunology, Washington University School of Medicine, Saint 
Louis, MO
The skin immune system includes a complex network of dendritic cells (DCs). In addition to gen-
erating cellular and humoral immunity against pathogens, skin DCs are involved in tolerogenic 
mechanisms that maintain immune homeostasis and in pathogenic chronic inflammation in which 
immune responses are unrestrained. Harnessing DC functions by targeting DC-derived molecules 
or by selectively modulating DC subsets is a promising future DC-based therapeutic approach. 
Characterization of functionally distinct DC subsets in mice has fueled interest in whether analo-
gous counterparts exist in humans. Transcriptional modules of coordinately expressed genes were 
utilized for defining shared functions between mouse and human DCs. Comparing modules derived 
for four human skin DC subsets, and modules derived from the Immunological Genome Project 
database for all mouse DC subsets, revealed that human Langerhans Cells (LCs) and the mouse 
XCR1+CD8a+CD103+ DCs shared the Class I-mediated antigen processing and cross-presentation 
transcriptional modules that, however, were not seen in mouse LCs. Furthermore, human LCs were 
enriched in a transcriptional signature specific to the blood cross-presenting CD141/BDCA-3+ DCs, 
the proposed equivalent to mouse CD8a+ DCs. Consistent with our analysis, LCs were highly adept 
at inducing primary CTL responses. Thus, our study suggests that the function of LCs may not be 
conserved between species and supports human LCs as an especially relevant therapeutic target. 
Homologies between the dermal human skin DC subsets and mouse DCs, as well as implications 
to the treatment of inflammatory skin diseases will be discussed.    
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Human skin is protected by four functionally and phenotypically discrete populations of 
resident and recirculating memory T cells
R Watanabe, A Gehad, C Yang, L Campbell, JE Teague, V Huang, TR Matos, TS Kupper and 
R Clark Dermatology, Brigham and Women’s Hospital, DF/BWH Cancer Center, Harvard 
Medical School, Boston, MA
The skin of an adult human contains approximately 20 billion memory T cells. Epithelial barrier 
tissues are infiltrated by a combination of resident and recirculating T cells in mice but the relative 
proportions and functional activities of resident versus recirculating T cells have not been evaluated 
in human skin. We discriminated resident from recirculating T cells in human engrafted mice and 
lymphoma patients using alemtuzumab, a medication that depletes recirculating T cells from skin, 
and then analyzed these T cell populations in healthy human skin. All non-recirculating resident 
memory T cells (TRM) expressed CD69, but the majority were CD4
+, CD103- and located in the der-
mis, in contrast to studies in mice. Both CD4+ and CD8+ CD103+ TRM were enriched in the epidermis, 
had potent effector functions and had a limited proliferative capacity compared to CD103- TRM. TRM 
of both types had more potent effector functions than recirculating T cells. Induction of CD103 on 
human T cells was enhanced by keratinocyte contact, depended on TGFβ and was independent 
of T cell-keratinocyte adhesive interactions. We observed two distinct populations of recirculating 
T cells, CCR7+/L-selectin+ central memory T cells (TCM) and CCR7
+/L-selectin- T cells, which we 
term migratory memory T cells (TMM). Circulating skin-tropic TMM were intermediate in cytokine 
production between TCM and effector memory T cells. In patients with cutaneous T cell lymphoma, 
malignant TCM and TMM induced distinct inflammatory skin lesions and TMM were depleted more 
slowly from skin after alemtuzumab, suggesting TMM may recirculate more slowly. In summary, 
human skin is protected by four functionally distinct populations of T cells, two resident and two 
recirculating, with differing territories of migration and distinct functional activities.    
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Novel STAT3 inhibitor LLL12 significantly reduces IL-17, IL-22, and IFN-gamma mRNA 
expression in psoriatic PBMCs
JG Hastings,2 X Zhang,1 J Lin,3 C Li4 and HK Wong2 1 Center for Biostatistics, OSU, 
Columbus, OH, 2 Division of Dermatology, Ohio State University, Columbus, OH, 3 College 
of Medicine, Dept of Pediatrics, OSU, Columbus, OH and 4 College of Pharmacy, Division 
of Medicinal Chemistry and Pharmacognosy, OSU, Columbus, OH
Psoriasis is a chronic immune skin disease characterized by epidermal inflammation and kerati-
nocyte proliferation where Th17 cells and their effector cytokines IL-17, IL-21, and IL-22 play an 
important role. STAT3 is a key transcription factor in the development and expression of Th17 genes. 
We studied the role of a novel STAT3 inhibitor, which possesses high affinity and specificity, on the 
ability to inhibit Th17 cytokine expression of peripheral blood mononuclear cells (PBMCs). Fresh 
PBMCs from patients with psoriasis and normal individuals without a history of skin disease were 
studied for expression of genes important in the pathogenesis of psoriasis. PBMCs were purified, 
incubated with various concentrations STAT3i, LLL12, and then stimulated with PMA and calcium 
ionophore A23187. RNA was extracted from the cells and quantified by qPCR. Compared to 
uninhibited controls, incubation with 1uM STAT3i for 60 minutes reduced IL-17 and IL-22 mRNA 
expression by 24 and 100-fold, respectively (p-value <0.0001 for both), while 0.1uM did not show 
significant inhibition. We tested increasing concentrations of STAT3i and a trend toward a dose-re-
sponse with inhibition starting at 0.25uM was noted. Additionally, IL-4 and interferon-gamma (IFN-g) 
were assessed to evaluate specificity to the Th17 pathway. Samples pretreated with STAT3i did not 
show significant inhibition of IL-4 mRNA (p=0.4265), and IFN-g, while not traditionally STAT3-de-
pendent, was reduced 9-fold by 1uM inhibitor (p=0.0004). Similar effects on these cytokines were 
noted in normal samples. These data show that small-molecule inhibition of STAT3 is significantly 
effective in reducing effector cytokine mRNA levels at a concentration of 1uM, is relatively specific 
to the Th17 pathway, and may have potential for development as a novel treatment for psoriasis.   
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GILT-mediated processing of a self and melanoma antigen in thymic epithelial cells promotes 
deletion and regulatory T cells
M Rausch,1 TC Metzger,2 M Waterfield,2 J Cortez,2 MS Anderson2 and KT Hastings1 1 
University of Arizona College of Medicine Phoenix, Phoenix, AZ and 2 University of California 
San Francisco, San Francisco, CA
Central tolerance is critical for the prevention of autoimmunity, but limits T cell responses to tumor 
antigens that are also self antigens. Previously, we identified that gamma-interferon-inducible lyso-
somal thiol reductase (GILT) is required for thymic deletion of CD4+ T cells specific for the self and 
melanoma antigen, tyrosinase-related protein 1 (TRP1). To define GILT’s role in central tolerance, 
we show that GILT expression is enriched in thymic antigen presenting cells (APCs) capable of 
mediating deletion, namely medullary thymic epithelial cells (TECs) and thymic dendritic cells. 
TRP1 expression is restricted to medullary TECs, consistent with Aire-mediated transcriptional reg-
ulation. GILT facilitates MHC class II-restricted presentation of endogenous TRP1 by pooled thymic 
APCs (TECs and bone marrow-derived APCs). Using bone marrow chimeras, we demonstrate that 
GILT expression in TECs is necessary and sufficient to mediate efficient deletion of TRP1-specific 
thymocytes. As anticipated, in chimeras that express GILT in TECs TRP1-specific T cells undergo 
thymic deletion and chimeras are not protected from melanoma challenge. Although an intermedi-
ate level of TRP1-specific T cells develop in chimeras in which GILT expression is limited to bone 
marrow-derived cells, only chimeras lacking GILT in both populations are protected from melanoma 
challenge. Consistent with these findings, chimeras that express GILT in TECs or in which GILT 
is limited to bone marrow-derived cells have a substantially higher percentage of TRP1-specific 
regulatory T cells and lower effector T cell to regulatory T cell ratio. These findings suggest that 
GILT operates in medullary TECs to facilitate the presentation of tissue-specific self antigens and 
promote deletion and development of regulatory T cells.    
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Dissecting the role of the CD27-CD70 pathway in Treg function in the skin
KA Remedios, H Truong, SV Gearty, ML Pauli, AK Abbas and MD Rosenblum UC San 
Francisco, San Francisco, CA
A subset of Tregs in human and murine skin are highly suppressive, stable memory cells that are 
functionally distinct from Tregs found in blood and secondary lymphoid organs. These cells have 
been termed memory Tregs (mTregs). The mechanisms that underlie skin-resident mTreg stability 
and function are unknown. The costimulatory receptor CD27 is a member of the TNFR family whose 
only known ligand is CD70. On non-Treg cells (i.e., effector T cells) the CD27-CD70 pathway has 
been shown to play a major role in memory T cell generation and function. We have recently shown 
that mTregs in skin express high levels of CD27; however, the function of this resceptor on mTregs 
is currently unknown. We hypothesize that the CD27-CD70 pathway is required for mTreg lineage 
stability and suppressive function in skin. To test this hypothesis, we have utilized mice deficient in 
CD27 and CD70. In the steady state, skin-resident mTregs from both CD27KO and CD70KO mice 
secrete more IL-17. Because Tregs share similar developmental pathways to the Th17 lineage, we 
explored the possibility that CD27-CD70 signaling stabilizes the Treg lineage by skewing away 
from Th17 differentiation. In a model of cutaneous c. albicans infection, skin-resident CD27 and 
CD70KO Teffs made more IL-17 relative to WT controls. Furthermore, at the peak of c. albicans 
infection, skin-resident CD27KO and CD70KO mTreg percentages were reduced. Finally, using an 
in vivo model of Treg competition, we found that CD27KO Tregs may be unstable due to loss of 
FOXP3 expression. Our data suggests that CD27-CD70 signaling may play a role in stabilizing the 
mTreg lineage in skin. Disruption of this pathway on mTregs may result in defective suppression of 
cutaneous immune responses upon repeated antigen exposure.    
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Autocrine neurokinin-1 receptor agonists induce T cell survival and promote potent cuta-
neous immunity
AT Larregina,1 D Rojas-Canales,2 TL Sumpter,1 W Shufesky,2 O Tkacheva1 and A Morelli2 1 
Dermatology, University of Pittsburgh, Pittsburgh, PA and 2 Surgery, University of Pittsburgh, 
Pittsburgh, PA
Skin chronic inflammatory disorders like contact hypersensitivity and psoriasis, require efficient 
development of type 1 T cell responses. Proinflammatory neuropeptides of the tachykinin family, 
including the neurokinin-1 receptor (NK1R)-ligands substance P (SP) and hemokinin-1 (HK-1), 
are known to promote innate and adaptive immunity, resulting in skin chronic inflammatory and 
autoimmune diseases. In the skin, proinflammatory neuropeptides are assumed to be secreted 
exclusively by Aδ and C nerve free endings. Nevertheless, the secretion source and the mechanisms 
utilized by NK1R-agonists to sustain skin innate and adaptive immunity remain poorly understood. 
Here, we investigated in vitro and in vivo, the source of SP and HK-1 and the effects that these 
neuropeptides exert on T-cell functions critical for the elicitation of cutaneous T-cell immunity. 
Using NK1R-/- mice in a model of delayed-type hypersensitivity (DTH) we demonstrate that the 
receptor is necessary for the development of skin innate and adaptive T cell mediated immunity. The 
pro-immune effects of signaling T cells via NK1R occurred in the absence of exogenous agonists. 
Skin and lymph node resident CD4 and CD8 T cells secreted HK-1 and SP to promote self-survival 
in an Ag specific manner. Mechanistically, autocrine signaling via NK1R promotes Il-2 transcription 
and IL-2 secretion by activating Ca+2 dependent- (NFAT1, NFAT2 and calcineurin) and independent- 
(c-Fos, c-Jun and -NF-kB) pathways. The effects of autocrine secreted HK-1 and SP were not further 
increased by exogenous addition of these neuropeptides. We conclude that autocrine secretion 
of NK1R agonists is necessary to protect T cells from apoptosis which results in sustained T cell 
dependent cutaneous immunity.    
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Calcium signaling for monitoring antigen-specific T cell stimulation
N Kibbi,2 E Hong,1 D Hanlon,2 R Edelson,2 T Fahmy1 and RE Tigelaar2 1 Biomedical 
engineering, Yale University, New Haven, CT and 2 Dermatology, Yale School of Medicine, 
New Haven, CT
There are few methods for directly tracking T cell responses during cancer immunotherapy. A 
method that tracks early T cell signaling events would offer rapid clinical assessment and allow 
therapeutic modifications. Understanding of the early signaling events in antigen-specific T cell 
activation continues to evolve: e.g., the flux of calcium ions into the cytoplasm is a well-charac-
terized early T cell activation event. Using calcium flux to indicate T cell signaling, we focused 
initially on the ovalbumin (OVA)-derived, SIINFEKL-specific transgenic mouse model (OT1). Naïve 
OT1 CD8+ T cells were mixed with SIINFEKL (specific)- or EIINFEKL (non-specific)-loaded dendritic 
cells (DC). By flow cytometry, we could not detect antigen-specific calcium flux (ACF) in OT1 
cells. We next mixed and pelleted DC and T cells to facilitate immunological synapse formation. 
We also labeled DC and T cells with anti-CD11c(FITC) and anti-CD8(PerCP/Cy5.5) respectively, 
which allowed gating on CD8+ CD11c+ conjugates. Conjugates represented T cells that had made 
stable contacts with DC. With this modification, we were able to detect ACF and showed that the 
peptide-loading concentration could be titrated down to ~10-3uM and the frequency of OT1 cells, 
when mixed with wild-type (WT; non-responding) cells down to ~0.1% OT1 cells. We next sought 
to identify the activation requirements of memory cells by examining the phenotype and functional 
potential of OT1 cells 6 weeks after adoptive transfer into WT recipients and immunization with 
OVA. Analysis of spleens, lymph nodes, and peripheral blood revealed that peripheral blood OT1 
cells were memory (CD127hi KLRG1lo) and short-lived (CD127lo KLRG1hi) effector cells, whereas 
OT1 splenocytes and lymph node cells remained early effector cells (CD127lo KLRG1lo). However, 
ACF could only be detected in the peripheral blood compartment. Herein, we have shown that ACF 
can be detected in naïve and memory T cells in a single-antigen, transgenic system from which we 
hope to develop a multi-antigen tumor model.    
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Cutaneous genetic vaccination targeting dermal DC subsets for enhanced antitumor immunity
Y Zhang, LD Falo and Z You University of Pittsburgh, Pittsburgh, PA
Skin harbors multiple DC subsets with different specialized functions and is the most accessible 
and ideal site for a vaccination. Understanding the contribution of distinct skin DC subsets in 
the cutaneous vaccination to the induction of effective tumor (antigen)-specific T cell immunity 
will provide important mechanistic insights and clinical implications for development of effective 
vaccines against cancer. Delivery of genetic vaccines encoding the transcription factor XBP1 and 
tumor antigens to dermal DC resulted in increased Type-1 IFN-α production by plasmacytoid DC 
from skin/tumor draining lymph nodes and the cross-priming of tumor (antigen)-specific CD8+ T cell 
responses associated with potent therapeutic benefit even in the clinically-reflective endogenous 
BrafV600E/Pten-driven melanoma model. Antitumor protection was dependent on skin migratory 
cross-presenting Batf3+ DC, plasmacytoid DC and CD8+ T cells. Dermal CD103+ DC from the skin/
tumor draining lymph nodes of the immunized mice were responsible for activation of vaccine 
antigen-specific naïve CD8+ T cells, and plasmacytoid DC were required for the optimal effective-
ness. Also, human XBP1 improved the capacity of human skin-derived DC to activate human T 
cells in vitro. Our findings suggest an important role for XBP1 in cutaneous vaccination for effective 
cross-priming and orchestration of the interactions between cross-presenting Batf3+ DC and Type-I 
IFN-producing plasmacytoid DC, thereby enabling to elicit robust, durable and effective protective 
antitumor immunity.    
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CCR2 presence is nonessential for acute and chronic psoriasisform skin inflammation 
Y Li, Y Fritz, JB Golden, D Diaconu, M Camhi, T McCormick and NL Ward Dermatology, 
Case Western Reserve University, Cleveland, OH
We previously identified increases in skin and circulating CD11b+Ly6Chi cells in KC-Tie2 and 
K5-IL-17C psoriasis mouse models and following acute topical Aldara application to C57Bl/6 (Bl/6) 
control mice (all p<0.05). CD11b+Ly6Chi monocytes are proinflammatory and play important roles 
in atherogenesis as prevention of their egress into circulation via genetic deletion of the chemokine 
receptor CCR2 attenuates atherogenesis. The contributions of CCR2 and circulating CD11b+Ly6Chi 
cells to acute and chronic psoriasiform skin inflammation remains unknown. To test the hypothesis 
that CCR2 is critical for the development of skin inflammation, we either applied topical Aldara 
or vaseline onto CCR2-/- and Bl/6 mice (n=6/grp) or backcrossed KC-Tie2 with CCR2-/- animals 
(n=3/grp) and then examined circulating and skin monocytes and severity of skin inflammation. 
CCR2-/- mice had significantly fewer splenic and skin-draining lymph node (SDLN; 3-fold; P<0.005) 
CD11b+Ly6Chi monocytes vs. Bl/6 mice at baseline and following topical Aldara (P<0.01). Mono-
cytes unexpectedly increased between vaseline and Aldara treatment in the CCR2-/- mice. KC-Tie2 
x CCR2-/- mice also displayed sustained monocytosis at KC-Tie2 levels mice in spleen and SDLN. 
Examination of skin histology from Bl/6 mice treated with Aldara revealed significant increases 
in CD4+, CD11c+, CD11b+ and F4/80+ cells and acanthosis (P<0.05 vs. Vaseline). CCR2-/- mice 
treated with Aldara responded similarly with the exception of CD11c+ cells, which remained at 
vaseline levels. Skin CD11c+ cells were also significantly decreased in KC-Tie2 x CCR2-/- vs. KC-Tie2 
animals (2-fold; P=0.02). Taken together these data suggest: a role for CCR2 in CD11c+ cell skin 
migration; that skin inflammation occurs independent of CD11c+ cells in the Bl/6 background 
strain; and that CCR2 is nonessential for the development of acute and chronic skin inflammation. 
Interestingly, skin inflammation elicited CD11b+Ly6Chi monocyte bone marrow egress using a 
CCR2-independent mechanism.    
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Regulatory T-cells suppress innate lymphoid cells in skin
AN Mathur,1 H Truong,1 AK Abbas2 and MD Rosenblum1 1 Dermatology, University of 
San Francisco California, San Francisco, CA and 2 Pathology, University of San Francisco 
California, San Francisco, CA
Group 2 innate lymphoid (ILC2s) are emerging as a central mediator of inflammation in atopic 
dermatitis (AD). Secretion of specific epithelial cytokines following barrier disruption results in 
ILC2 activation and subsequent coordination of Th2 dominant immune responses. In contrast, 
regulatory T cells (Tregs) suppress skin inflammation. Mice and humans who lack functional Tregs 
develop a severe atopic-like inflammatory skin disease. The cellular and molecular mechanisms 
of how cutaneous ILC2 cells are regulated and what role skin-resident Tregs play in this process 
are currently unknown. Here, we show that the application of the Vitamin D3 analog (MC903) on 
shaved back and ear skin of Rag2-/- mice induces an atopic-like dermatitis after 7 days, as mea-
sured by characteristic histologic changes and a 3-fold increase in ear thickness. Flow cytometric 
analysis of collagenase-digested skin demonstrates a marked influx of inflammatory monocytes 
(CD11b+LyG-Ly6C+), eosinophils (CD11b+SinglecF+), neutrophils (CD11b+Ly6G+), and NK cells 
(NK1.1+). Mice lacking ILCs (Rag2-/-IL2Rγc-/-) are completely protected from MC903-dependent 
inflammation, suggesting that ILCs are critical for skin disease in this model. To determine if Tregs 
abrogate ILC2 dependent disease, Rag2-/- were treated with MC903 for 7 days and adoptively (or 
sham) transferred with purified Tregs. Mice receiving Tregs demonstrated a 2-fold reduction in the 
number of neutrophils (p=0.02) and a 6-fold reduction in the number of inflammatory monocytes 
(p=0.03) compared to MC903-treated control mice. Our results indicate that Tregs may directly 
inhibit ILC2-dependent inflammation, suggesting a novel mechanism of Treg-dependent immune 
regulation. Future studies aim to elucidate the molecular mechanisms by which Tregs control 
ILC2-driven skin inflammation.    
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Induction of skin resident and systemic T-cell immunity by cutaneous immunization using 
dissolvable microneedle arrays
BE Friedman,1 C Carey1 and LD Falo1, 2, 3 1 Department of Dermatology, University 
of Pittsburgh School of Medicine, Pittsburgh, PA, 2 Clinical and Translational Science 
Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA and 3 Department of 
Bioengineering, University of Pittsburgh, Pittsburgh, PA
We have previously demonstrated that dissolvable microneedle arrays (MNAs) can co-deliver bio-
logically active cargos to the APC-rich skin microenvironment while avoiding systemic distribution. 
As intradermal immunization has been shown capable of generating skin-resident non-circulating 
memory T-cells (TRM cells) that provide sustained immune surveillance, we sought to determine 
whether MNA vaccination could induce systemic and skin resident TRM-mediated antigen-spe-
cific immunity. OVA-specific immunity was evaluated in mice immunized with MNAs integrating 
OVA (MNA-OVA), or OVA and Poly(I:C) (MNA-OVA-Poly[IC]), or by intramuscular (IM) injec-
tions with the same quantity of antigen and/or adjuvant. MNA-OVA immunization induced potent 
systemic CTL immunity compared to IM immunization, (MNA-OVA = 75.2% lysis, IM OVA = 
2.0% lysis) but less that MNA-OVA-Poly[IC] (96.5% lysis). Further, OT-1 cell infused mice immu-
nized with MNA-OVA-Poly[IC] demonstrated recruitment and proliferation of cytokine expressing 
OT-1 cells in the skin, and a substantially increased population of skin-resident memory T-cells 
(CD8+CD45.2+CD103+). Taken together these results demonstrate the potential of MNA adminis-
tered adjuvanted vaccines to induce both potent systemic immunity and long-term TRM mediated 
immunity in the skin.    
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Pediatric atopic dermatitis is characterized by increased T-cell activation with aberrant T-cell 
development
H Esaki1, 2, T Czarnowicki,1 J Gonzalez,1 D Malajian1, 2, S Talasila,3 A Berry,3 J Gray,3 
S Noda,1 JG Krueger,1 E Guttman-Yassky1, 2 and AS Paller3 1 Laboratory for Investigative 
Dermatology, The Rockefeller University, New York, NY, 2 Department of Dermatology, 
Icahn School of Medicine at Mount Sinai, New York, NY and 3 Department of Dermatology 
and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
Despite the pediatric predominance of atopic dermatitis (AD), the initial stages of immune acti-
vation in AD are poorly understood. Defining blood biomarkers for pediatric AD is important 
for development of pathogenesis-driven therapies for children. To define the development and 
activation of memory T-cell subsets in pediatric AD patients versus controls, surface markers and 
intracellular cytokine staining were identified by flow cytometry of blood from 16 children (<5yo) 
and 16 age-matched healthy children. IFNg+, IL-9+, IL-13+, IL-17+, and IL-22+ -polarized cells were 
measured in CLA+ skin homing and CLA- CD4+ and CD8+ T-cells. We identified a lower frequency 
of circulating CLA+ Th1 (7.5% vs. 15.6%; p=0.007) and higher frequency of circulating CLA+ Th2 
(4.0% vs. 9.5%; p=0.04) in AD children. Moreover, the CLA+ Th1:Th2 ratio was significantly lower 
in pediatric AD vs. controls (1.3% vs. 10.0%; p=0.01). Disease severity (by SCORAD) correlated 
with both CLA+ Th2 and Th2:Th1 ratio (r=0.59; p=0.03 and r=0.51; p=0.04, respectively). In normal 
children parallel increases with age occurred in CLA+ Th1 and Th2 T-cell populations, but Th1 
T-cell expansion did not occur in AD children, despite progressive Th2 activation. Using ICOS 
as a marker of T-cell activation, a higher state of T-cell activation was detected in AD children 
(p<0.01). These data establish early onset AD in children as a disease of immune activation which 
is associated with failure to achieve age-appropriate Th1 development, possibly allowing aberrant 
Th2 expansion within skin-homing T-cell populations.    
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Skin-mediated promotion of thrombosis is abrogated following IL-23/IL-17 inhibition or IL-6 
deletion in mouse models of psoriasis
JB Golden,1 Y Fritz,1 Y Li,1 Y Wang,2 DI Simon,2 T McCormick1 and NL Ward1 1 Derm, Case 
Western Reserve University, Cleveland, OH and 2 Cardiovascular Medicine, Case Western 
Reserve University, Cleveland, OH
Psoriasis patients are at increased risk of dying of heart attack and stroke and have elevated S100A8/9 
levels, which are predictive of poor cardiovascular event outcomes. S100A9-/- mice develop less 
atherosclerosis and are protected against thrombosis. KC-Tie2 mice develop a psoriasiform skin 
phenotype, have elevated skin and serum S100A9 and are pro-thrombotic. We hypothesized that 
genetic deletion of S100A9 in KC-Tie2 mice would improve skin disease and thrombosis. However 
thrombosis was similar between KC-Tie2 x S100A9-/- and KC-Tie2 mice (n=14-20/grp; P=0.9), 
perhaps due to persistent skin inflammation, elevated pro-inflammatory cytokines including IL-6, 
IL-17A, IL-12/23 (n=9-12; ~5-6-fold; P<0.05) and sustained circulating Ly6Chi monocytes (n=3-7; 
~1.5-fold; P<0.05). To explore the contributions of these cytokines in promoting thrombosis, we 
backcrossed KC-Tie2 with IL-6-/- mice or treated KC-Tie2 mice with clinically validated cytokine 
function blocking antibodies targeting IL-17A, IL-17RA, IL-12p40, and IL23p19 (n=7-14/grp). 
Thrombosis returned to control mouse levels in KC-Tie2 x IL-6-/- mice (n=14-20) and was signifi-
cantly improved in KC-Tie2 mice treated with each of the cytokine function blocking antibodies 
vs. IgG controls (P<0.05 each). Improvement in skin inflammation was only observed in KC-Tie2 
mice treated with antibodies, not KC-Tie2 x IL-6-/- animals, consistent with clinical reports of skin 
improvement following IL-23/IL17 pathway inhibition, but not IL-6. Although we hypothesized that 
circulating monocytes contribute to atherothrombosis, neither IL-6 deletion nor functional inhibition 
of IL-23/IL-17 pathways decreased levels of circulating monocytes, despite improving thrombosis. 
These data reveal a critical role for skin-derived IL-6 and the IL-23/IL-17 pathways in promoting 
thrombosis related to psoriasiform inflammation and also rule out CD11b+Ly-6Chi monocytes as 
necessary for thrombotic events in the KC-Tie2 mouse model.    
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Effect of enteric viral infection on graft-versus-host disease severity
K Eash, M Cooper, T Nice and JF DiPersio Washington University School of Medicine, Saint 
Louis, MO
Graft-versus-host disease (GVHD) is the major non-relapse cause of morbidity and mortality in hema-
topoietic cell transplantation (HCT) via immune mediated target organ damage, most commonly 
cutaneous or gastrointestinal tissue. The bacterial component of the host microbiome increases 
immune activation and resulting severity of GVHD, but the role of the viral component of the 
microbiome is unknown. We hypothesized that, in a manner analogous to intestinal bacterial flora, 
enteric viral infection would worsen GVHD. To test this hypothesis, MHC mismatched bone marrow 
(BM) cells with or without splenic T cells were transplanted into lethally irradiated recipient mice 
(H-2b —> H-2d) in a standard acute GVHD model system. Two weeks later, a cohort of recipients 
was also infected with murine norovirus (MNV, strain CR6), an enteric RNA virus endemic to 
mouse facilities. Surprisingly, while there was nearly 100% lethality as expected in control mice, 
we observed increased survival in MNV infected recipients, with 40% of mice surviving to day 
65 post-transplant (median survival 38 vs 60 days, p = 0.02, n = 20 per group). MNV infection, 
which normally persists at low levels without clinical symptoms, was partially cleared in mice 
with GVHD. Infection was also associated with decreased numbers of circulating leukocytes, B 
cells, and T cells. Further experiments demonstrated that MNV inoculated acutely (1 day) after 
irradiation failed to establish persistent infection or affect GVHD severity. Additionally, allografts 
derived from persistently MNV infected donor mice did not alter the severity of GVHD despite clear 
infection-induced alterations in the immunophenotype of the BM and spleen. These results suggest 
that variation in the eukaryotic virome, via interaction the intestinal mucosal immune system and/
or commensal bacteria, is protective against GVHD.    
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Individual naïve T cells give rise to both TRM and TCM during immune responses in vivo
O Gaide,1 RO Emerson,2 X Jiang,1 R Clark1 and TS Kupper1 1 Dermatology, Brigham & 
Women’s Hospital, Boston, MA and 2 Adaptive Biotech, Seattle, WA
The generation of memory T cells from naive T cells is incompletely understood. There are different 
hypotheses regarding the generation of different memory subsets, but most accept the “one cell-
one fate” model, which holds that a given naive T cell can become (for example) either a central 
memory T cell (TCM) or and effector memory T cell (TEM), but not both. Competing models hold that 
this process is stochastic, or dictated by TCR affinity, or by micro-environmental factors. We have 
previously shown that skin immune responses generate both TCM and TRM. In this study, we use 
high throughput sequencing to study the naive T cell progenitors of these cells. Using three distinct 
antigenic challenges to skin (a protein, a hapten, and a poxvirus) and high throughput sequencing 
(HTS) of the TCR Vβ gene, we selected skin TRM clones (with unique Vβ CDR3 sequences) that 
were undetectable in skin or LN prior to antigen exposure, but abundant in skin (>5 copies/400ng 
gDNA) at >30 days after antigen encounter. For all three antigenic challenges, we found that the 
same clones (identical CDR3’s) were present in TRM from antigen treated skin and distant skin, and 
TCM from draining and distant LN. From 8-18 clones fit this criteria for all antigens combined, with 
a mean TRM clone size of 18 cells/400ng gDNA in skin. At least 93% of such clones were also 
present as TCM in distant lymph nodes, with a mean clone size of 16 cells/400ng gDNA. This was 
not a function of peripheral blood contamination, as in a parallel experiment only one of the top 
ten clones found in blood was also found in skin and LN. We again demonstrated that in vivo, TRM 
are responsible for rapid responses to antigen challenge, while TCM respond in a delayed fashion. 
Therefore, HTS allows us to say that after skin antigen encounter, the same naive T cell differentiates 
into both TRM and TCM lineages, the first evidence in vivo that a single naive T cell can have more 
than one memory lineage fate.    
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ENTPD1 and PD-1/PD-1 ligands are highly expressed by skin-resident immune cells in subsets 
of human SCC 
C McCray,1 J Cook,1 R Streilein,1 S Degan,2 W Havran,3 JY Zhang1, 4 and AS MacLeod1, 4 1 
Department of Dermatology, Duke University, Durham, NC, 2 Surgery, Duke University, 
Durham, NC, 3 Immunology and Microbial Science, The Scripps Research Institute, Durham, 
NC and 4 Skin Disease Research Center, Duke University, Durham, NC
Skin-resident immune cells, including T cells and myeloid cells, provide protection against environ-
mental threats and cancer. Our previous studies in mice have shown that UV radiation (UVR)-in-
duced epithelial DNA damage, a major risk factor for squamous cell carcinoma (SCC), is limited 
by murine skin-resident T cells. This strategy of ‘immune surveillance’ involves the release of the 
danger signaling molecule ATP leading to enhanced skin-resident T cell activation. However, 
despite an existing immune cell network, human skin often succumbs to SCC, and the underlying 
mechanisms are incompletely understood. We recently identified that the ATPase ectonucleoti-
dase 1 (ENTPD1) is highly upregulated in human SCC in contrast to healthy skin, as quantified 
by both qPCR (p=0.03,n>5 per group) and flow cytometry (p=0.00007, n>5 per group). ENTPD1 
is not only the rate-limiting enzyme for adenosine generation, but has been recently described as 
a novel immune checkpoint. Furthermore, we demonstrate here that 54.6%+27.9% (mean+SD, 
n>5 per group) of ENTPD1+CD14+ cells co-expressed PD-1 ligand, whereas skin-resident (i.e. 
CLA+) ENTPD1+ T cells were majorly regulatory (i.e. FoxP3+) and 59.5%+8.6% co-expressed PD-1, 
suggesting immune-regulatory functions. Using flow cytometry and qPCR we identified that IL-27 
was expressed in human SCC by CD14+ cells but not in healthy skin, and was sufficient to induce 
ENTPD1 and PD-L1 on myeloid cells in vitro. In skin-resident T cells, IL-27 increased the frequency 
of human FoxP3+ cells by approximately 3-fold and supernatants from skin T cells pretreated with 
IL-27 lost their ability to augment DNA repair upon UVB damage, measured by γH2AX staining in 
human keratinocytes (p=0.01, n=3). Together, our data suggest a previously unrecognized role for 
IL-27-regulated immune checkpoints and DNA repair in human SCC.    
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Two populations of skin CD4 memory T cells with distinct migratory properties after C. 
albicans infection
C Park,1 R Clark,1 RC Fuhlbrigge,1 X Jiang,1 T Tian,1 C Lin,2 X Fu,3 R Watanabe1 and 
TS Kupper1 1 Dermatology, Brigham & Women’s Hospital, Boston, MA, 2 Harvard Medical 
School, Boston, MA and 3 Mass General Hospital, Boston, MA
The migratory properties of skin CD4 T cells in mice have not been characterized. We used a model 
of skin C. albicans infection in mice adoptively transferred with KAEDE CD4 T cells. KAEDE-green is 
irreversibly photoconverted to KAEDE-red after violet light exposure. We performed in vivo imaging 
studies on mice at 45 and 90 days after infection, and examined previously infected skin at 24 hours 
after violet light exposure. Both KAEDE-red and KAEDE-green CD4 T cells could be identified at 
this time: KAEDE-red CD4 T cells populated superficial dermis and moved slowly(mean velocity 
1.72mm/min; arrest coefficient>50) while KAEDE-green CD4 T cells populated deep dermis and 
were rapid movers(3.05mm/min, AC<50). At day 90 after infection, stable KAEDE-red CD4 TRM cells 
were present superficial dermal area(1.58mm/min; AC>75), while rapid moving KAEDE-green CD4 
T cells(2.69mm/min; AC<60) were present in the deep dermis. We next tested for expression the 
TRM markers CD69 and CD103. Slow-moving upper dermal KAEDE-red CD4 TRM cells expressed 
significant levels of CD69 and CD103, while the fast moving KAEDE-green cells in deep dermis 
were negative for these markers. To test whether KAEDE green CD4 cells had migrated into the 
photoexposed skin from blood, we examined skin immediately after violet light exposure(0h). At this 
time, 100% of CD4 T cells extracted from skin were KAEDE-red. However, by 6 hours after violet 
light exposure, fast moving KAEDE-green CD4 T cells had already appeared in the photoconverted 
area, indicating recent entry into skin. These cells were highly migratory(5.30mm/min; AC<25) in 
the deep dermis, while persisting upper dermal KAEDE-red CD4 T cells moved more slowly(2.78 
mm/min). These results indicate two populations of CD4 memory T cells in previously infected 
skin; slow-moving upper dermal CD69+CD103+TRM that do not migrate, and faster moving T cells 
that lack canonical TRM markers that enter dermis from blood with kinetics measured in hours.   
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Dust mite is a strong activator of IL-17 pathway genes and is distinct from the atopic der-
matitis skin phenotype
B Ungar1, 2, S Garcet,2 A Shemer,3 JG Krueger2 and E Guttman-Yassky1, 2 1 Dermatology, 
Icahn School of Medicine at Mount Sinai, New York, NY, 2 Laboratory for Investigative 
Dermatology, The Rockefeller University, New York, NY and 3 Tel-Hashomer, Tel-Aviv, Israel
The atopy patch test (APT) using house dust mite (HDM) antigen elicits eczematous reactions in 
a large percent of atopic dermatitis (AD) patients. Since no animal model reproduces the AD skin 
pathology, the APT HDM model has been used to simulate AD lesions for research or therapeutic 
evaluations. We sought to assess whether this model accurately represents acute or chronic AD by 
comparing the molecular and cellular phenotypes of positive HDM reactions from individuals with 
and without AD (n=14) to acute and chronic skin phenotypes of AD patients (n=10), using microar-
rays, RT-PCR, and immunohistochemistry. Using criteria of fold change/FCH>2.0 and FDR<0.05 
to define differentially expressed genes (DEG) vs. non-lesional skin, we identified 2711 and 1147 
DEGs in APT skin of AD and non-AD individuals, respectively, vs. only 458 and 1583 DEGs in 
acute and chronic AD, respectively, with a small number of DEGs overlapping between APT and 
AD. CD3+ T-cells and CD11c+ dendritic cell infiltrates were significantly increased in APT com-
pared to acute and chronic AD skin (p<0.05). APT induced robust increases in Th17/IL-17 pathway 
genes, including IL-17F (FCH=76.1), lipocalin 2 (FCH=11.6), S100A7/A8/A9 (FCH=72/59.7/58.5), 
DEFB4A (FCH=167.7), CCL20 (FCH=7.0) (all p<0.05), with accompanying large increases in IL-9 
(FCH=2.9x104), and IL-5 (FCH=29.9) genes; all p<0.05. Key Th2 AD genes (e.g. Th2/IL-4, IL-10, 
OX40L, IL-31) and Th1/interferon-regulated genes (IFNg, CXCL9) were only induced in AD lesions 
(FCH>2, p<0.05). Many down-regulated genes in AD lesions (e.g. lipids) were not mirrored in 
APT reactions. In sum, APT reactions showed much larger inflammatory responses and differential 
polarization compared to acute or chronic AD tissues. While AD is Th2/Th22- polarized with Th1 
and Th17 components, APT is primarily Th17-skewed, and lacks key features required for a good 
AD skin model.    
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Global screening for skin homing program genes in CD8+ T cells after live viral immunization
Y Pan, T Tian, C Park, S Lofftus, SJ Divito, RC Fuhlbrigge and TS Kupper Dermatology, 
Brigham & Women’s Hospital, Boston, MA
Previous work has shown that after Vaccinia virus(VACV) infection of skin, antigen specific CD8+ 
T cells in the lymph node draining the infected site begin to proliferate at 24-48 hours, and by 60 
hours, cells can be identified that have divided from 0-5 times (P0-P5). Imprinting of T cells with skin 
homing molecules is presumed to be initiated during this series of cell divisions, as judged by CFSE 
dilution and FACS. While certain factors have been implicated in the acquisition of a skin homing 
phenotype, no global unbiased approach has yet been applied to this process. In order to accomplish 
this, we loaded OT-1 T cells with CFSE, injected them into syngeneic mice, and 24 hours later 
immunized by skin scarification with VACV-ova, which expresses the OT-1 peptide under a VACV 
early gene promoter. At 60 hours after immunization, we obtained draining lymph nodes and sorted 
cells that had undergone between 0 and 5 cell divisions, as determined by CFSE. RNA was extracted 
from these cells, and was analyzed by transcriptional profiling. Hierarchical clustering of 225 genes 
showing more than 1.5-fold changes in expression revealed that robust gene expression alteration 
occurred from P0-P5 cell divisions. Subsequent gene ontology (GO) and gene co-expression network 
were conducted to identify core regulatory genes associated with skin specific homing. Consistent 
with their corresponding cell surface expression, gene expression of CD62L was down-regulated 
from P0-P5 while gene expression of α4 integrin was not altered. The α(1,3)-fucosyltransferases 
(FUT4 and FUT7), which catalyze the synthesis of the selectin binding tetrasaccharide moiety 
on CLA, were up-regulated from P0-P2, and then stabilized. Sphingosine-1-phosphate receptor 1 
(S1PR1), which promotes T-cell egress from the lymphoid organs, was down-regulated from P0 to 
P2, and then up-regulated from P2-P5. From these data, we can begin to build a genetic blueprint 
for acquisition of the skin homing phenotype in activated T cells.    
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The proteasome inhibitor Bortezomib inhibits the function of peripheral dendritic cells and 
induces apoptosis
Z Lai1, 2 and TM Ruenger1 1 Dermatology, Roger Williams Medical Center/Boston University, 
Providence, RI and 2 Division of Bone Marrow Transplantation, Roger Williams Medical 
Center/Boston University, Providence, RI
The 26S proteasome degrades ubiquitin-tagged proteins to eliminate abnormal proteins and to 
maintain cellular protein homeostasis. Bortezomib is a specific inhibitor of the 26S proteasome 
and is approved for the treatment of multiple myeloma and mantle cell lymphoma. Except for 
mild neurotoxicity, treatment with Bortezomib is usually well tolerated. In a clinical phase 1 trial, 
Bortezomib was recently shown to prevent graft-versus-host disease (GvHD) in patients who are 
receiving bone marrow transplants. This effect was thought to be mediated by alteration of dendritic 
cell (DCs) function, as it was accompanied by reduced expression of activation markers in peripheral 
DCs. As DCs play critical roles in the development of GvHD, our goal was to further characterize 
effects of Bortezomib on peripheral DCs. Using concentrations that are comparable to serum con-
centrations reached during clinical use of Bortezomib (5 - 10 nM), we studied function and survival 
of DCs isolated from peripheral blood of healthy donors. Morphologically, a loss of dendricity was 
observed in treated DCs. Antigen-presentation function was studied using the ovalbumin antigen 
presentations assay in co-culture with CD4+ T cells, and was reduced by 40% (24 hour time point; 
n=5, p<0.05). Production of IL-12 by DCs, which is critical for activation of CD4+ T-cells and Th1 
polarization was also reduced 50% by Bortezomib (n=5, p<0.01). Bortezomib was mildy toxic to 
DCs, e.g. resulting in death of 10 % of the treated cells (24 hour time point; n=5, p<0.05). This was 
due to apoptosis, as shown by increased caspase 3 activities. These data provide further evidence 
for the inhibitory effects of Bortezomib on peripheral DCs, and support the notion that it is not 
only an effective agent to treat hematologic malignancies and to prevent GvHD, but may also be 
effective to treat conditions that are driven by DCs, e.g. autoimmune diseases.    
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Topical application of an epidermal growth factor receptor kinase inhibitor enhances the 
response to influenza vaccination
BP Pollack1, 2, I Skountzou,3 JA Pulit-Penaloza,3 RW Compans,3 B Sapkota2 and ES Esser3 1 
Atlanta VAMC, Decatur, GA, 2 Dermatology, Emory University School of Medicine, Atlanta, 
GA and 3 Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA
Systemic use of epidermal growth factor receptor inhibitors (EGFRIs) has been shown to alter MHC 
expression and that of several chemokines, and to enhance immune cell recruitment into human 
skin. We hypothesized that EGFRIs may have value as cutaneous immune response modifiers, and 
determined the effects of topical application of an irreversible EGFRI on a well-established murine 
model of influenza vaccination. We found that a single topical application of an EGFRI led to 
increased levels of antibodies that inhibit influenza mediated hemagglutination and viral cytopathic 
effects. The topically applied EGFRI significantly enhanced the generation of vaccine-specific IL-4 
and IFN-γ producing cells within skin-draining lymph nodes as early as one week following vac-
cination. The EGFRI-treated group showed a twelve-fold reduction in detectable pulmonary viral 
load four days after infection as compared to the unadjuvanted vaccine control. The reduction in 
the lung viral titers correlated with the survival rate, which demonstrated 100% protection in the 
EGFRI-vaccine immunized group but only 65% protection in the mice immunized with unadju-
vanted vaccine. These findings are significant because they demonstrate that inhibition of defined 
signaling pathways within the skin using small molecule kinase inhibitors provides a novel approach 
to enhance immune responses to vaccines.    
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Responses to influenza vaccine after rituximab therapy in patients with autoimmune blis-
tering diseases
A Cho,1 B Bradley,2 L Priyamvada,1 Y Kovalenkov,1 RJ Feldman2 and J Wrammert1 1 
Pediatrics, Emory University, Atlanta, GA and 2 Dermatology, Emory University, Atlanta, GA
Autoimmune blistering diseases (AIBD) are an uncommon group of B-cell mediated diseases result-
ing from pathogenic autoantibodies directed against cellular adhesion proteins in the skin and 
mucous membranes. B cell depletion therapy with Rituximab has recently demonstrated efficacy in 
these patients. However, data regarding B cell reconstitution and antigen-specific B cell responses 
following therapy are lacking. Importantly, clinical recommendations regarding influenza vaccina-
tion and potential responses to vaccines post-Rituximab therapy have not been reported in AIBD 
patients. In this ongoing study, patients with AIBD whom received Rituximab therapy within the 
last two years were vaccinated against influenza, and the immune responses to vaccination were 
compared to age and sex matched healthy controls. Patients had varied levels of B cell reconsti-
tution at time of vaccination (median time post-treatment: 11 mo., range: 3-16 mo). Samples were 
analyzed for influenza-specific plasmablast responses and serology via HAI/neutralization assays 
at pretreatment, one week and one month following vaccination. Interestingly, AIBD patients with 
detectable reconstitution of B cells were able to generate influenza-specific plasmablast responses 
at a magnitude comparable to that of healthy controls. ELISPOT also demonstrated that the response 
was dominated by class-switched IgG, peaking at day 7 post-vaccination in both groups, suggestive 
of a recall response. This is despite the six-fold lower number of peripheral memory B cells found 
in patients compared to healthy controls (p<0.0001). Data from this study will help to address 
the clinically relevant issue of when to vaccinate AIBD patients against influenza following B cell 
depletion therapy, and determine the need for alternative vaccination strategies, including high dose 
vaccines or additional booster doses. Further studies of this interesting patient cohort will also pro-
vide insight into basic human B cell biology as well as B cell mediated AIBD-specific pathogenesis.   
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Vitiligo T cell receptor SILv44 imparts a Tc17 profile and anti-tumor reactivity on host T cells
J Eby,1 J Klarquist,1 M Li,3 D Wainwright,1 S Watkins,1 W Westerhof,2 C Paulos,3 S Mehrotra,3 
E Garrett-Mayer,3 R Luiten,2 M Nishimura1 and C Le Poole1 1 Oncology Research 
Institute, Loyola University Chicago, Maywood, IL, 2 University of Amsterdam, Amsterdam, 
Netherlands and 3 Medical University of South Carolina, Charleston, SC
We questioned the role of T cell receptors (TCRs) in defining functional differences among auto-
immune and tumor reactive T cells. We thus probed the reactivity of TCRs reactive with the same 
antigenic peptide from vitiligo and melanoma patients, after expression within the same host cells. 
For these studies, we propagated T cells from depigmenting skin, identified a gp100-reactive TCR 
named SILv44 for ‘skin infiltrating lymphocytes from vitiligo’, and cloned it into a retroviral vec-
tor to allow a comparison to TCRs R6C12 and T4H2 from circulating melanoma T cells upon T 
cell transduction. Although melanoma patients were peptide gp100209-2M vaccinated to drive high 
avidity T cell responses, greatest IL-2 secretion was observed by SILv44 expressing CD8+ Jurkats. In 
transduced CD8+ primary human T cells, SILv44 expressing CTL responded to 888A2+ melanoma 
cells by enhanced CD107A surface expression and IL-17A secretion; the latter was also observed in 
response to melanocytes. Importantly, cytokine expression by TCR transduced T cells shifted from 
IFN-γ to IL-17A by limiting peptide availability to physiologic concentrations. Superior anti-tumor 
efficacy of SILv44 transduced T cells was observed in vivo, where IL-17A expressing T cells limited 
the growth of 888A2+ tumors in SCID/beige mice. This comparison provides surprising cues about 
TCR contributions to T cell plasticity, supporting a role for TCR variable regions in defining T cell 
cytokine secretion patterns and function. The data further suggest that vitiligo patient skin can 
provide a valuable source of T cell receptors with therapeutic potential in melanoma.    
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Tissue basophilia in Stat6VT mice, a T cell-dependent model of atopic dermatitis
A Thyagarajan-Sahu,1 LJ Seymour,1 VN Nemeth,1 MH Kaplan2 and MJ Turner1 1 Dermatology, 
Indiana University, Indianapolis, IN and 2 Pediatrics, Microbiology & Immunology, Indiana 
University, Indianapolis, IN
Tissue basophilia has been reported in lesional skin of patients with atopic dermatitis (AD); however, 
the role of these cells in disease remains to be defined. Mouse models of AD include those that 
require T cells (T cell-dependent) and those that do not (T cell-independent). Recent work in a T 
cell-independent model induced by topical application of a 1,25-dihydroxyvitamin D3 analogue 
(MC903) demonstrated basophils infiltrate AD-like lesional skin and mediate the disease phenotype. 
To determine if basophils are similarly involved in T cell-dependent models of AD, we evaluated 
lesional and nonlesional skin in Stat6VT transgenic mice. Quantitative PCR revealed increased 
expression (~10 fold) of the basophil-specific transcript Mcpt8 in lesional skin from Stat6VT mice 
in comparison to nonlesional and WT skin; a similar pattern of expression was noted in MC903-in-
duced AD-like lesions (compared to vehicle-treated skin). Analysis of enzymatically digested skin 
samples by flow cytometry identified basophils (CD49b+, FceR1a+) in the skin of WT and Stat6VT 
mice. In comparison to skin from WT mice, the percentage and total number of basophils was 
increased 2-3 fold in nonlesional skin and 9-10 fold in lesional skin samples from Stat6VT mice. 
Peripheral basophilia (~2-3 fold increase in cell count) was also noted in the blood and spleen 
of diseased Stat6VT mice compared to WT controls. Interestingly, basophil counts were similarly 
increased in Stat6VT mice with no visible AD-like disease demonstrating systemic basophilia pre-
cedes development of the AD phenotype in this model. These findings suggest basophils could 
play a role in development of AD-like disease in Stat6VT mice, thereby providing a novel model 
in which to investigate the contribution of these cells to T-cell dependent AD-like inflammation.   
